Jay B. Lichter
InvestorManaging Partner at Avalon BioVentures · Board director at Enlaza Therapeutics · Board director at Cellular Approaches · Board director at Cullinan Mica
Rancho Santa Fe, California, United States
Find your path to Jay
259 people in our graph share verified history with Jay — schools, employers, funds. One of them is your warm intro.
Michael TaylorunlockedJay: together at Pfizer (1999–2000)
×3Jay: together at University of Illinois Urbana-Champaign
×3Jay: together at University of Illinois Chicago
×3Jay: together at Pfizer
About
Managing Partner with over 30 years of experience in investing, operations, scientific research, and business development. Led investments in Aratana, Synthorx, Janux, and Nerio, generating over $4B in exits and $800M+ in realized gains. Holds a PhD from the University of Illinois.
Contact· self-published, not guessed
Board director at Enlaza Therapeutics
Intro paths
→
In turn, Jay can intro founders to Enlaza Therapeutics's investors below.
Enlaza Therapeutics's investors · 8
Avalon BioVenturesSan Diego · since 2025Frazier Life SciencesPalo Alto · since 2025J.P. Morgan Asset ManagementLightspeed Venture PartnersMenlo Park · $1.7M – $87M checksOrbiMedNew York · $1M – $75M checks · since 2025Pappas CapitalDurhamPfizer Venture Investments$5M – $20M checksSamsara BioCapitalPalo Alto · since 2025
Co-founders at Enlaza Therapeutics
SD
Sergio DuronCo-Founder & Chief Executive Officer
SM
Sanford MadiganCo-Founder, President & Chief Business Officer
Board director at Cellular Approaches
Intro paths
→
In turn, Jay can intro founders to Cellular Approaches's investors below.
Cellular Approaches's investors · 1
Board director at Cullinan Mica
Intro paths
→
In turn, Jay can intro founders to Cullinan Mica's investors below.
Cullinan Mica's investors · 1
Experience
- Avalon BioVenturesManaging Partnercurrent2022 — present
- Arialys TherapeuticsPresident and CEOcurrent2021 — presentLa Jolla, CA
- Avalon VenturesManaging Directorcurrent2007 — present
- Avalon VenturesPresident and CEO2006 — 2008
- Pacific Ridge SchoolTrustee2009 — 2016Carlsbad, CA
- Aratana Therapeutics IncChairman Of The Board2010 — 2015
- Afraxis, IncPresident and CEO2008 — 2012
- ReVision Therapeutics, Inc.President and CEO2010 — 2011
- CarolusChairman2007 — 2009
- SyteraCOO2004 — 2006
- SequenomeVP Business Development2002 — 2004
- PfizerManager1999 — 2000
- GensetExecutive Vice President1998 — 1999
- SequanaDirector1993 — 1998
- DuPont MerckPost-Doc1992 — 1993
Skills & more
Leadership13Management10Negotiation4Strategic Planning6Strategy8Biotechnology52Lifesciences28Venture Capital38Pharmaceutical Industry29Mergers & Acquisitions34Entrepreneurship32Licensing12
+12 more
Business DevelopmentPatentsIntellectual PropertyBusiness StrategyCorporate DevelopmentCommercializationStart-upsInvestmentsDrug DiscoveryInvestor RelationsMergersBiochemistryFrom Jay's professional profile.
Deals · 3
Cullinan MicaBoard seat
via Avalon BioVentures · filed Mar 2022 · $10M raise
Cellular ApproachesBoard seat
via Avalon BioVentures · filed Nov 2016 · $5.1M raise
Arista MDBoard seat
via Avalon BioVentures · filed Mar 2016 · $1.4M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Per SEC Form D filings.
Colleagues at Avalon BioVentures
Abby Beers
FP&A Manager at Avalon BioVentures
Adrienne Terrazas
Executive Admin at Avalon BioVentures
Bryce Suchomel
Advisor at Avalon BioVentures
Christy Sayers
Head of Human Resources at Avalon BioVentures
Eben Massari
Advisor at Avalon BioVentures
Fernando Camejo
Senior Accounting Manager at Avalon BioVentures
Jason Roland
Advisor at Avalon BioVentures
Jill Mooney
Advisor at Avalon BioVentures
Frequently asked questions
- Who is Jay B. Lichter?
- Managing Partner with over 30 years of experience in investing, operations, scientific research, and business development. Led investments in Aratana, Synthorx, Janux, and Nerio, generating over $4B in exits and $800M+ in realized gains. Holds a PhD from the University of Illinois.
- Where does Jay B. Lichter work?
- Jay B. Lichter is Managing Partner at Avalon BioVentures and Board director at Enlaza Therapeutics and Board director at Cellular Approaches and Board director at Cullinan Mica.
- What boards does Jay B. Lichter sit on?
- Jay B. Lichter holds tracked board seats at AristaMD, Cellular Approaches, Cullinan Mica, Enlaza Therapeutics, Synthorx.
- Where did Jay B. Lichter go to school?
- Jay B. Lichter studied at University of Illinois Chicago (Ph.D, Biochemistry); University of Illinois Urbana-Champaign (BS, Biochemistry).
Same school
Also attended University of Illinois Chicago95
Sam BlackmanEntrepreneur in Residence at GV (Google Ventures)Kate WilschutzChief Financial Officer, Revolution Funds at RevolutionSteve ShafferOperating Partner at Volition CapitalAnshul SadanaCEO, Nexthop AI at EMERGENT VENTURESStefano GaliassoVice President at Energy Capital VenturesBoris GyllhamnInvestment Manager at Almi Invest GreenTech
+ 89 more
Also attended University of Illinois Urbana-Champaign740
Max LevchinCo-founder of PayPal; founder, chairman & CEO of Affirm; partner at SciFi VCLuke NosekCo-founder of PayPal; co-founder of GigafundSundeep PeechuGeneral Partner at Felicis VenturesDeep NisharInvestment Team at General CatalystPrashant ShahPartner at Monta Vista CapitalNoorPartner at Clear Ventures
+ 734 more
Shared employers
Also worked at Aratana Therapeutics Inc1
Also worked at ReVision Therapeutics, Inc.1
Also worked at Sequenom8
Nola MastersonVenture Fund Partner at PortfoliaBill WelchVenture Partner at Illuminate VenturesHyuk-Jeen SuhGeneral Partner at SkyRiver VenturesCharlie RodiFounder and CSO at RhoDxMichael TolentinoExecutive Officer, Director at Aviceda TherapeuticsJustin J. FileExecutive Officer at Evofem Biosciences
+ 2 more
Also worked at Pfizer288
Jigar RaythathaInvestor at Third Rock VenturesAbbie CelnikerInvestor at Third Rock VenturesErin MooreInvestor at Third Rock VenturesJeb KeiperInvestor at Third Rock VenturesRichard ChesworthInvestor at Third Rock VenturesMichael TaylorOperating Partner at Mission Biocapital
+ 282 more